Abstract 122P
Background
Neurotrophic Tyrosine Receptor Kinase gene fusions are oncogenic drivers involving either NTRK1, NTRK2 or NTRK3 (encoding the tropomyosin receptor kinases TRKA, TRKB and TRKC, respectively). The overall prevalence of NTRK fusion-positive tumors is ∼0.30%, though frequencies vary by tumor type, with >90% reported for some rare tumor types such as secretory carcinoma of the breast and salivary glands. In Europe the TRK inhibitors (TRKi) entrectinib and larotrectinib, have both received tumor-agnostic approval based on pooled data of non-comparative phase I/II clinical trials with limited patient numbers, both showing high clinical activity and favorable safety profiles.
Methods
REALTRK is a retro- and prospective, observational, intersectoral, multicenter cohort study in Germany and Switzerland (NCT04557813) investigating patients (pts) with advanced solid tumors harboring an NTRK fusion diagnosed with a validated assay according to ESMO recommendations. Enrollment of 120 pts is planned. Pts with detailed information on NTRK testing qualify for complete documentation, including demographic and clinical characteristics, details on NTRK testing, treatment, outcome, and safety of TRKi. Furthermore, physician-reported factors on NTRK testing and treatment decision making as well as patient-reported outcomes on quality of life (EORTC QLQ-C30) are assessed.
Results
At data cut-off (Apr 28th, 2023), 32 pts have been enrolled at 20 sites in Germany and Switzerland. 16 pts were eligible for complete documentation. Significant heterogeneity regarding pts, tumor types, and NTRK fusions was observed, including pts with ECOG status between 0 and 3, 7 different tumor entities, and 11 different NTRK1/2/3-fusion partners.
Conclusions
The tumor-agnostic cohort study REALTRK provides a challenging and unique opportunity to collect extremely rare and valuable data on NTRK testing and treatment reality of a very small pts population with NTRK fusion-positive solid tumors. Although the heterogeneity between pts and tumor types makes interpretation of the data and comparison to clinical trial data difficult, REALTRK offers the opportunity to collect important real-world evidence.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
iOMEDICO AG.
Funding
Roche Pharma GmbH.
Disclosure
S. Lange: Financial Interests, Institutional, Research Grant: Illumina, Inc.; Financial Interests, Institutional, Invited Speaker: Janssen-Cilag GmbH, MSD Sharp & Dohme GmbH, FALKFoundation e.v.B. Kasenda: Financial Interests, Personal, Invited Speaker: Roche Pharma GmbH; Financial Interests, Institutional, Advisory Board: Roche Pharma GmbH, Astellas Pharma GmbH. M. Zaiss: Financial Interests, Personal and Institutional, Speaker’s Bureau: AbbVie, MSD Sharp & Dohme GmbH, Roche Pharma GmbH, Takeda, Vifor; Financial Interests, Institutional, Advisory Board: AbbVie, AstraZeneca, BMS, Celgene, Eisai, Gilead, Hexal, Janssen-Cilag GmbH, Lilly, Novartis, Pfizer, Roche Pharma GmbH, Vifor. U.M. Martens: Financial Interests, Institutional, Advisory Board: BMS, Roche Pharma GmbH, GSK, Novartis, Pierre Fabre, Guardant Health, MSD Sharp & Dohme GmbH. C. Batereau: Financial Interests, Personal, Invited Speaker: Roche Pharma GmbH. T. Decker: Financial Interests, Personal and Institutional, Advisory Board: Novartis Pharma GmbH, iOMEDICO AG. O. Waidmann: Financial Interests, Personal, Invited Speaker: Amgen, AstraZeneca, Bayer, BMS, Eisai, Ipsen, MSD, Novartis, Roche; Financial Interests, Personal, Advisory Board: Amgen, AstraZeneca, Bayer, BMS, Celgene, Eisai, Incyte, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pierre Fabre, Roche, Servier; Financial Interests, Personal, Research Grant: Medac, Merck KGaA. C. Vannier: Financial Interests, Personal, Full or part-time Employment: Pierre Fabre Pharma GmbH. All other authors have declared no conflicts of interest.
Resources from the same session
93P - A new platform for fast-track molecular stratification of endometrial carcinomas enabling timely treatment decisions in precision oncology
Presenter: Susanne Walz
Session: Cocktail & Poster Display session
Resources:
Abstract
94P - Harnessing circulating tumor DNA in bronchoalveolar lavage fluid for precise molecular diagnosis of NSCLC
Presenter: Frank Borm
Session: Cocktail & Poster Display session
Resources:
Abstract
95P - Automatic data processing to identify EGFR mutations in pathology reports of patients with non-small cell lung cancer (NSCLC)
Presenter: Betzabel Cajiao Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
96P - Analysis of concordance between microsatellite instability by next generation sequencing (NGS-MSI) and mismatch repair deficiency by immunohistochemistry (IHC-MMR) in endometrial cancer (EC) patients
Presenter: Simona Duranti
Session: Cocktail & Poster Display session
Resources:
Abstract
97P - Prospects of liquid biopsy in determining prognosis in children with HGG and DIPG
Presenter: Olga Regentova
Session: Cocktail & Poster Display session
Resources:
Abstract
98P - Liquid biopsy in NSCLC: A promising tool to predict immunotherapy response
Presenter: Ana Fernández
Session: Cocktail & Poster Display session
Resources:
Abstract
99P - Comprehensive genomic sequencing as an ancillary diagnostic tool for pathologists
Presenter: Dan Miller
Session: Cocktail & Poster Display session
Resources:
Abstract
100P - Standard serum biomarkers to help predict a cancer diagnosis in patients with non-specific symptoms: Data from Guy´s rapid diagnostic clinic
Presenter: Maria Monroy Iglesias
Session: Cocktail & Poster Display session
Resources:
Abstract
101P - Patient-derived organoids to optimize CDK4/6 inhibitor-based treatment selection in early breast cancer
Presenter: Carla Alves
Session: Cocktail & Poster Display session
Resources:
Abstract
102P - MicroRNAs in urine and saliva as non-invasive biomarkers of minimal residual disease in pediatric acute lymphoblastic leukemia
Presenter: Alejandra Pando-Caciano
Session: Cocktail & Poster Display session
Resources:
Abstract